top of page
The Human Variable
Search


Recalibrating the Demographic Landscape of ME/CFS in the United States
Using CYNAERA’s US-CCUC™ model, we present a corrected demographic landscape grounded in published science, epidemiological data, and terrain-calibrated prevalence modeling. For the first time, undocumented immigrant populations and ancestral dietary biology are incorporated as visible drivers of disease prevalence. Our analysis demonstrates that half of Americans with ME/CFS are non-white, and that prevalence in certain groups is likely higher when adjusted for baseline into
Aug 25, 2025


Comprehensive ME/CFS Overview – Correcting Undercounts and the Global Public Health Crisis
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating, multi-system neuroimmune disease on par with multiple sclerosis or congestive heart failure in severity, but for decades, it’s been sidelined by global health systems. Underdiagnosis, outdated clinical criteria, systemic bias, and institutional inertia have obscured its true scale. The result: tens of millions worldwide excluded from diagnosis, care, or recognition.
Aug 24, 2025


Composite Diagnostic Fingerprint for ME/CFS
The CDF-ME framework captures between 88–94% of patients who meet International Consensus Criteria (ICC), Canadian Consensus Criteria (CCC), or the National Academies of Sciences, Engineering, and Medicine (NASEM) diagnostic criteria, regardless of whether their illness was triggered by infection, vaccination, physical trauma, or environmental exposure. Validated through CYNAERA’s AI engine and over 200,000 patient simulations, CDF-ME integrates high-specificity markers .
May 14, 2025


A Nobel-Scale Advance: AI-Powered CRISPR Platform to End Infection-Associated Chronic Conditions - Lite
A Nobel-scale leap, built outside the system. This isn’t just another CRISPR project. CYNAERA’s AI-powered gene editing platform was designed by a patient, for patients—modeling remission across millions of synthetic profiles to restore immune stability in infection-associated chronic conditions like Long COVID, ME/CFS, and MCAS.
It cuts years off clinical trial timelines. It eliminates $5–10 million in early development costs. It’s scalable and ethical globally. AI meets bio
May 8, 2025


The Pathophysiology of Infection-Associated Chronic Conditions
Infection-associated chronic conditions (IACCs) such as Long COVID, ME/CFS, POTS, and MCAS are not disparate diagnoses — they are systemic sequelae following immune injury. For too long, medicine has treated these illnesses as anomalies or mysteries, when in fact, they follow a biologically predictable pattern of dysregulation.
Apr 29, 2025


Data Privacy in Chronic Illness Management: Trusting AI with Your Health
As AI technology continues to revolutionize healthcare, one crucial aspect that cannot be overlooked is data privacy and security.
Apr 11, 2025
bottom of page
